No Data
No Data
Roth MKM Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $19
Roth MKM analyst Jonathan Aschoff maintains $Zevra Therapeutics(ZVRA.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success rate of 28.9% a
Express News | Zevra Therapeutics Inc Files for Mixed Shelf Offering of up to $350 Mln- SEC Filing
Express News | Zevra Therapeutics Announces Phase 2 Trial Results For KP1077 In Idiopathic Hypersomnia Presented At SLEEP 2024
Express News | Zevra Therapeutics Inc - Kp1077 Was Well Tolerated
Zevra Therapeutics Announces Positive Final Results From Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) today announced that final positive results from its placebo-controlled, double-blind Phase 2 clinical trial (NCT05668754) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate or SDX) in patients with idiopathic hypersomnia (IH) were presented in a poster at SLEEP 2024, the 38th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, held in Houston, TX, June 1-5, 2024.
Express News | Zevra Therapeutics Announces Positive Final Results From Phase 2 Clinical Trial of Kp1077 for Idiopathic Hypersomnia at Sleep 2024 Annual Meeting
No Data